IntrinsicIntrinsic
← All summaries

Biofrontera Inc.

BFRI
Financials & Chart →

Business Summary

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products for dermatological conditions, specifically photodynamic therapy (PDT) . The company's primary products, Ameluz and the RhodoLED and RhodoLED XL lamp series (collectively, "RhodoLED Lamps"), are utilized for the treatment of actinic keratosis (AK), a common pre-cancerous skin lesion . The company generates revenue by directly selling its products to dermatology offices and groups through its national commercial team .

The core business model revolves around the sale of Ameluz, a prescription drug, in combination with the RhodoLED Lamps for PDT . Ameluz PDT is an in-office procedure, and Ameluz is distributed as a "buy-and-bill" drug, meaning dermatologists purchase it directly rather than through pharmacies . When the product is used in a treatment, a payor is billed, and the provider is reimbursed for both the product and the light treatment . The company's revenue is subject to some seasonality, historically being higher during the first and fourth quarters of the year compared to the second and third quarters, as traditional PDT treatments are performed more frequently in winter .

Ameluz, in combination with the RhodoLED Lamps, is approved in the United States for the lesion-directed and field-directed treatment of mild-to-moderate actinic keratosis on the face and scalp . AKs are superficial pre-cancerous skin lesions caused by sun exposure that can develop into squamous cell carcinoma if left untreated . PDT is a two-step process involving the application of a photosensitizer drug that accumulates in fast-growing cells, followed by activation with a selective light source to destroy these cells . Ameluz PDT therapy is highly effective, with up to 91% clearance after one or two treatments and limited or no scarring . The therapy may also provide protection from the progression of mild AKs . The RhodoLED XL lamp, approved by the FDA in 2021 and launched in June 2024, allows for the illumination of larger areas, enabling simultaneous treatment of multiple distant AKs . The smaller BF-RhodoLED model continues to be offered .

For the fiscal year ended December 31, 2025, Biofrontera reported total net revenues of $41.705 million , an increase from $37.321 million in 2024 . Product revenues, net, specifically increased by $4.4 million, or 11.8%, compared to 2024, primarily driven by organic growth in Ameluz sales volume of $4.1 million and a $0.7 million increase due to a higher Ameluz unit price . This growth was partially offset by a $0.3 million decline in RhodoLED Lamps sales . The company's gross profit improved due to a reduction in cost of revenues, related party, which decreased by $7.7 million, or 43.4%, compared to 2024 . This reduction was a result of transitioning from a transfer pricing model to a significantly lower cost structure, with the cost of revenues per unit reducing to approximately 5% beginning in July 2025, compared to a range of approximately 25% to 50% of revenue for sales in 2024 and through June 1, 2025 . Additionally, $2.1 million of purchase price accrued for units bought in 2025 under the previous agreement was forgiven . These decreases were partially offset by earnout payments of $2.2 million made in 2025 under the new agreements .

Total operating expenses for 2025 were $53.053 million , a decrease from $54.531 million in 2024 . Loss from operations improved to $(11.348) million in 2025 from $(17.210) million in 2024 . Net loss for 2025 was $(10.536) million , an improvement from $(17.759) million in 2024 . Basic and diluted EPS for 2025 was $(1.04) , compared to $(3.22) in 2024 . Cash and cash equivalents as of December 31, 2025, were $6.392 million , up from $5.905 million at December 31, 2024 . The company had convertible notes payable of $4.589 million as of December 31, 2025 , and $4.098 million as of December 31, 2024 . The accumulated deficit as of December 31, 2025, was $127.9 million .

Significant operational developments during the period include the Strategic Transaction on October 20, 2025, where Biofrontera Inc. acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG and its consolidated subsidiaries (the "Biofrontera Group") . This transaction involved Biofrontera AG receiving 3,019 shares of Series D Convertible Preferred Stock and an earnout agreement where Biofrontera Inc. will pay 12% of U.S. Ameluz revenues when sales are $65.0 million or less, and 15% when sales exceed $65.0 million, until patent expiration . This new structure is expected to reduce overall costs and accelerate the company's path to break-even . Effective June 1, 2024, the company assumed control of all clinical trials for Ameluz in the U.S. . In October 2024, the FDA approved an increase in the maximally approved dosage of Ameluz from one to three tubes per treatment . Also in October 2024, the company received Phase III trial results for Ameluz PDT as a treatment for superficial basal cell carcinoma (sBCC), showing 65.5% success in the composite endpoint compared to 4.8% with placebo-PDT . A Supplemental New Drug Application for sBCC treatment was submitted to the FDA in November 2025, with a Prescription Drug User Fee Act date of September 28, 2026 . Furthermore, a new formulation of Ameluz without propylene glycol was approved by the FDA, extending patent protection to 2043 . On November 6, 2025, the company completed the sale of the intangible asset related to its Xepi product line for initial proceeds of $3 million, with potential for up to an additional $7 million in milestone payments .

Business Outlook

The company's principal objective is to improve patient outcomes through the adoption and use of its products in the United States . Key elements of its strategy include expanding sales of Ameluz in combination with the RhodoLED Lamps for AK treatment, aiming to position Ameluz as the standard of care by acquiring new customers and growing the therapy within its existing customer base . The company also plans to leverage the potential for future approvals and label extensions for Ameluz in the U.S. market, furthering its clinical development after taking over responsibility for certain ongoing clinical trials since June 1, 2024 . Additionally, the company intends to strategically manage its portfolio, including opportunistically adding complementary products or services through acquisitions or licensing of intellectual property to leverage its commercial infrastructure and customer relationships .

One major growth area is the label expansion for Ameluz. The company submitted a Supplemental New Drug Application to the FDA in November 2025 for the approval of Ameluz PDT for the treatment of superficial basal cell carcinoma (sBCC) using the BF-RhodoLED or RhodoLED XL lamp, with a Prescription Drug User Fee Act date set for September 28, 2026 . Another growth vector is the expansion of Ameluz for actinic keratosis (AK) on the trunk and extremities. The last-patient-out of the treatment phase for this Phase III study occurred in Q3 2025, with the Clinical Study Report (CSR) expected in Q2 2026 . A regulatory filing for a supplemental New Drug Application (sNDA) for field treatment of AKs on extremities and neck and trunk is expected for Q3 2026 . A pharmacokinetics study for AK on the trunk and extremities, applying three tubes of Ameluz, had its last-patient-out in Q4 2025, with the CSR expected in Q2 2026 and regulatory filing anticipated with the Phase III study in Q3 2026 . The company also plans to start enrollment in 2027 for an Ameluz study focused on AK Pain Reduction . Furthermore, the new, larger RhodoLED XL lamp, approved by the FDA in 2021 and launched in June 2024, enables illumination of larger areas, supporting the simultaneous treatment of several distant AKs . The FDA's October 2024 approval to increase the maximally approved dosage of Ameluz from one to three tubes per treatment provides greater flexibility for healthcare professionals in addressing larger or multiple treatment areas, which is foundational to supporting the planned trunk and extremities label expansion .

Operationally, the company aims for consistent revenue growth and expanding operating margins . It is focused on product sales expansion to drive revenue growth and improve operating efficiencies, including effective resource utilization, information technology leverage, and overhead cost management . The Strategic Transaction, effective October 20, 2025, is expected to reduce overall costs and accelerate the company's timeframe to reach break-even by transitioning from a transfer pricing model to a significantly lower cost structure . Under the new arrangement, the cost of revenues per unit reduced to approximately 5% beginning in July 2025, compared to a range of approximately 25% to 50% of revenue previously . The company also assumed full control of the Ameluz New Drug Application and Investigational New Drug, enabling independent management of ongoing and future clinical development activities and full responsibility for manufacturing and marketing Ameluz and RhodoLED lamps in the U.S. .

The company's R&D programs are focused on label expansion for Ameluz and improving the capabilities of the RhodoLED Lamps . R&D expenses for 2025 increased by $1.6 million compared to 2024, primarily due to the company's full-year responsibility for Ameluz clinical trial activities in the U.S. . Planned capital allocation includes continued R&D expenditures to improve RhodoLED Lamps and potentially develop new products . The company has financed its operating and capital expenditures through cash proceeds from product sales, convertible notes, and equity financings . In 2025, it received $11.0 million in gross proceeds from a private placement of Series C Preferred Stock . The company plans to address its going concern conditions by expanding Ameluz commercialization, controlling expenses, realizing an additional $1.0 million in milestone payments from the Xepi asset sale, and, if necessary, securing additional capital through equity or debt financings .

The company explicitly flagged several structural headwinds and execution risks. There is substantial doubt about its ability to continue as a "going concern" due to significant losses and the need to raise additional funds . The company has a history of operating losses and anticipates continued losses, with no assurance of achieving or sustaining profitability . Failure to obtain additional financing could prevent the pursuit of strategic growth plans, potentially leading to delays or discontinuation of commercialization efforts or R&D programs . Existing and future indebtedness could adversely affect operations by requiring cash dedication to debt payments, increasing vulnerability to adverse economic changes, and limiting flexibility . Geopolitical instability, trade disputes, and tariffs, particularly on European imports, could materially increase costs, disrupt the supply chain, and adversely affect the business . The company is also subject to the risk that the U.S. market size for Ameluz for AK treatment may be smaller than estimated .

Risk Factors

The company faces several material risks, including substantial doubt about its ability to continue as a going concern, with unaudited cash of $3.6 million as of March 11, 2026 , and an accumulated deficit of $127.9 million as of December 31, 2025 . Geopolitical instability, trade disputes, and tariffs, particularly on European imports, could materially increase costs and disrupt the supply chain, as products are exclusively imported from Europe . The company is involved in intellectual property lawsuits, including a complaint alleging patent infringement related to its RhodoLED-XL lamp, where an Initial Determination found the Sun Patents valid and importation of RhodoLED XL to violate Section 337 of the Tariff Act of 1930 . However, a final written decision on February 23, 2026, found all challenged claims in one of the SUN Patents to be unpatentable . Failure to comply with extensive healthcare laws and regulations, including anti-fraud and abuse laws, could lead to penalties, fines, and operational restrictions . Product recalls or serious safety issues, such as the voluntary recall of Ameluz in February 2024 due to a manufacturing defect in packaging, could negatively impact the company . The company is highly dependent on key personnel, and the inability to attract and retain qualified individuals could hinder business strategy implementation . The results of R&D efforts are uncertain, and there is no assurance they will enhance commercial success .

Management Priorities

Management's message to shareholders emphasizes a principal objective to improve patient outcomes through the adoption and use of the company's products, primarily Ameluz and the RhodoLED Lamps, in the United States. They are focused on expanding sales of Ameluz for actinic keratosis (AK) and positioning it as the standard of care by acquiring new customers and growing the therapy within the current customer base. A key strategic priority is leveraging the potential for future approvals and label extensions for Ameluz in the U.S. market, which includes furthering the clinical development of the product after assuming responsibility for ongoing clinical trials since June 1, 2024. Another strategic priority is opportunistically adding complementary products or services to the portfolio by acquiring or licensing intellectual property to further leverage existing commercial infrastructure and customer relationships. Management believes that executing these strategic objectives will fuel growth, deepen relationships in the dermatology community, and ultimately help patients. The company's long-term financial objectives include consistent revenue growth and expanding operating margins, driven by product sales expansion and improved operating efficiencies.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Ameluz and RhodoLED Lamps
  5. [5] Item 1, Business — Sales, marketing and distribution
  6. [6] Item 1, Business — Sales, marketing and distribution
  7. [7] Item 1, Business — Seasonality
  8. [8] Item 1, Business — Ameluz and RhodoLED Lamps
  9. [9] Item 1, Business — Ameluz and RhodoLED Lamps
  10. [10] Item 1, Business — Ameluz and RhodoLED Lamps
  11. [11] Item 1, Business — Ameluz and RhodoLED Lamps
  12. [12] Item 1, Business — Ameluz and RhodoLED Lamps
  13. [13] Item 1, Business — Our R&D programs
  14. [14] Item 1, Business — Our R&D programs
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Product Revenues, net
  18. [18] Item 7, MD&A — Product Revenues, net
  19. [19] Item 7, MD&A — Cost of Revenues, Related Party
  20. [20] Item 7, MD&A — Cost of Revenues, Related Party
  21. [21] Item 7, MD&A — Cost of Revenues, Related Party
  22. [22] Item 7, MD&A — Cost of Revenues, Related Party
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Liquidity and Capital Resources
  31. [31] Item 7, MD&A — Liquidity and Capital Resources
  32. [32] Item 8, Consolidated Balance Sheets
  33. [33] Item 8, Consolidated Balance Sheets
  34. [34] Item 7, MD&A — Liquidity and Capital Resources
  35. [35] Item 7, MD&A — Strategic Transaction
  36. [36] Item 7, MD&A — Strategic Transaction
  37. [37] Item 7, MD&A — Strategic Transaction
  38. [38] Item 7, MD&A — Strategic Transaction
  39. [39] Item 7, MD&A — Overview and Recent Developments
  40. [40] Item 1, Business — Our R&D programs
  41. [41] Item 1, Business — Our R&D programs
  42. [42] Item 1, Business — Our R&D programs
  43. [43] Item 1, Business — Our R&D programs
  44. [44] Item 7, MD&A — Strategic Transaction
  45. [45] Item 7, MD&A — Strategy
  46. [46] Item 7, MD&A — Strategy
  47. [47] Item 7, MD&A — Strategy
  48. [48] Item 7, MD&A — Strategy
  49. [49] Item 1, Business — Our R&D programs
  50. [50] Item 1, Business — Our R&D programs
  51. [51] Item 1, Business — Our R&D programs
  52. [52] Item 1, Business — Our R&D programs
  53. [53] Item 1, Business — Our R&D programs
  54. [54] Item 1, Business — Our R&D programs
  55. [55] Item 1, Business — Our R&D programs
  56. [56] Item 7, MD&A — Strategy
  57. [57] Item 7, MD&A — Strategy
  58. [58] Item 7, MD&A — Strategic Transaction
  59. [59] Item 7, MD&A — Cost of Revenues, Related Party
  60. [60] Item 7, MD&A — Strategic Transaction
  61. [61] Item 7, MD&A — Overview and Recent Developments
  62. [62] Item 7, MD&A — Research and Development Expense
  63. [63] Item 1A, Risk Factors — Risks Related to Our Financial Position and Capital Requirements
  64. [64] Item 7, MD&A — Strategy
  65. [65] Item 7, MD&A — Liquidity and Capital Resources
  66. [66] Item 7, MD&A — Liquidity and Capital Resources
  67. [67] Item 1A, Risk Factors — Risks Related to Our Financial Position and Capital Requirements
  68. [68] Item 1A, Risk Factors — Risks Related to Our Financial Position and Capital Requirements
  69. [69] Item 1A, Risk Factors — Risks Related to Our Financial Position and Capital Requirements
  70. [70] Item 1A, Risk Factors — Risks Related to Our Financial Position and Capital Requirements
  71. [71] Item 1A, Risk Factors — Geopolitical instability, trade disputes, and tariffs imposed on imports could materially increase our costs, disrupt our supply chain, and adversely affect our business, financial condition, and results of operations.
  72. [72] Item 1A, Risk Factors — The United States market size for Ameluz for the treatment of AK may be smaller than we have estimated.
  73. [73] Item 1A, Risk Factors — There is substantial doubt about our ability to continue as a "going concern."
  74. [74] Item 1A, Risk Factors — There is substantial doubt about our ability to continue as a "going concern."
  75. [75] Item 1A, Risk Factors — Geopolitical instability, trade disputes, and tariffs imposed on imports could materially increase our costs, disrupt our supply chain, and adversely affect our business, financial condition, and results of operations.
  76. [76] Item 20, Commitments and Contingencies — Legal Claims
  77. [77] Item 20, Commitments and Contingencies — Legal Claims
  78. [78] Item 1A, Risk Factors — We are subject to extensive laws and regulations. Our failure to comply with those laws and regulations could have a material adverse effect on our business, reputation, results of operations, and financial condition.
  79. [79] Item 1A, Risk Factors — A recall of our drug or medical device products, or the discovery of serious safety issues with our drug or medical device products, could have a significant negative impact on us.
  80. [80] Item 1A, Risk Factors — We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may be unable to successfully implement our business strategy.
  81. [81] Item 1A, Risk Factors — The results of our R&D efforts are uncertain and there can be no assurance they will enhance the commercial success of our products.

Analysis on 5/22/2026